9.29
+0.925(+11.06%)
Currency In USD
| Previous Close | 8.37 |
| Open | 9.55 |
| Day High | 9.99 |
| Day Low | 9.02 |
| 52-Week High | 17.18 |
| 52-Week Low | 2.69 |
| Volume | 246,871 |
| Average Volume | 40,504 |
| Market Cap | 24.86M |
| PE | -0.39 |
| EPS | -23.81 |
| Moving Average 50 Days | 7.53 |
| Moving Average 200 Days | 6.51 |
| Change | 0.93 |
If you invested $1000 in NextCure, Inc. (NXTC) since IPO date, it would be worth $38.9 as of November 13, 2025 at a share price of $9.29. Whereas If you bought $1000 worth of NextCure, Inc. (NXTC) shares 5 years ago, it would be worth $73.38 as of November 13, 2025 at a share price of $9.29.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
GlobeNewswire Inc.
Yesterday at 1:00 PM GMT
BELTSVILLE, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to developing novel therapies to treat cancer, today announced that it has entered into definitive agreements wit
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
GlobeNewswire Inc.
Oct 16, 2025 12:05 PM GMT
First U.S. patient dosed at a mid-tier dose level where multiple responses have been observedMulti-regional trial to accelerate time to proof-of-concept data in 1H 2026 BELTSVILLE, Md. and SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc.
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 04, 2025 11:00 AM GMT
BELTSVILLE, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced